Video

Dr. Alva on TKI Monotherapy and Combinations for RCC

Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.

Ajjai Shivaram Alva, MBBS, an associate professor at the University of Michigan, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma (RCC).

TKIs have a continuing role in RCC therapy, either as a single agent for patients with favorable-risk disease in which TKIs appear superior to immunotherapy, or in combination with immunotherapy, explains Alva. The FDA approved 2 combinations for frontline RCC therapy: axitinib (Inlyta) plus avelumab (Bavencio) and axitinib plus pembrolizumab (Keytruda).

There are a few other combinations that are expected to read out soon, including lenvatinib (Lenvima) plus pembrolizumab and cabozantinib (Cabometyx) plus nivolumab (Opdivo), says Alva. TKI combinations for intermediate- and poor-risk patients are likely going to evolve in the upcoming years, concludes Alva.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity